Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system.

Cheng, Guofeng; Chan, Katie; Yang, Huiling; Corsa, Amy; Pokrovskii, Maria; Paulson, Matthew; Bahador, Gina; Zhong, Weidong; Delaney, William

Cheng, Guofeng; Chan, Katie; Yang, Huiling; Corsa, Amy; Pokrovskii, Maria; Paulson, Matthew; Bahador, Gina; Zhong, Weidong; Delaney, William.

Affiliation

Cheng G; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA. guofeng.cheng@gilead.com

Antimicrob Agents Chemother ; 55(5): 2197-205, 2011 May.

Article in En | MEDLINE | ID: mdl-21357305

Subject(s)

Antiviral Agents/pharmacology; Hepacivirus/drug effects; Hepacivirus/genetics; Protease Inhibitors/pharmacology; Cell Line; Drug Resistance, Viral/genetics; Humans; Reverse Transcriptase Polymerase Chain Reaction

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antiviral Agents / Protease Inhibitors / Hepacivirus Limits: Humans Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antiviral Agents / Protease Inhibitors / Hepacivirus Limits: Humans Language: En Year: 2011 Type: Article